Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibition

We report the characterization of two methods for the analysis of N-acetyl-aspartyl-glutamate (NAAG) in biological fluids. In the first method, NAAG concentrations were calculated based on differences between glutamate concentrations before and after NAAG hydrolysis with exogenous glutamate carboxyp...

Full description

Saved in:
Bibliographic Details
Published in:Analytical biochemistry 2010-09, Vol.404 (1), p.94-96
Main Authors: Thomas, Ajit G., Rojas, Camilo J., Hill, Jeanette R., Shaw, Michael, Slusher, Barbara S.
Format: Article
Language:English
Subjects:
Biomarkers - cerebrospinal fluid
Chromatography, High Pressure Liquid - methods
Dipeptides - cerebrospinal fluid
Glutamate Carboxypeptidase II - antagonists & inhibitors
Glutamate Carboxypeptidase II - metabolism
Humans
Hydrolysis
Tandem Mass Spectrometry - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the characterization of two methods for the analysis of N-acetyl-aspartyl-glutamate (NAAG) in biological fluids. In the first method, NAAG concentrations were calculated based on differences between glutamate concentrations before and after NAAG hydrolysis with exogenous glutamate carboxypeptidase II (GCP II) using high-performance liquid chromatography (HPLC) followed by fluorescence detection. In the second method, NAAG levels were quantified directly using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Analyses of NAAG levels in human cerebrospinal fluid samples using either method gave similar results within experimental error, confirming the validity of the two independent measurements. These methods will be useful in future clinical trials to assess drug-induced GCP II inhibition in biological matrices.
ISSN:0003-2697
1096-0309
DOI:10.1016/j.ab.2010.04.029